Menu ×

HEALTHCARE & PHARMACEUTICAL

Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Analysis by Treatment Type (Drug Treatment, and Surgical Treatment); by Therapeutic Class {BPH Devices (Transurethral RF Thermal Therapy, Suture Base Implant, and Others), and BPH Drugs (Alpha Blocker, Muscarinic Receptor Antagonist, 5-Alpha Reductase Inhibitors)}; and by Distribution Channels (Online, Pharmacies, and Institutional Sales) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2033

  • Text Size:

Inflation And Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.

Request Insights

Purchasing power in the couPurchasing power in the country is expected to fell nearly by 2.5%. On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.                                                         Request Insights

Read More

IN THE NEWS

  • NxThera, Inc. to that its Rezum System is more effective and provides long-lasting comfort in benign prostatic hyperplasia (BPH).  Rezum System is also found quicker in results than other pharmaceutical agents.

  •  Teleflex Incorporated announces the results of research studies regarding the efficacy and safety of UroLift Systems. The system is developed for men diagnosed with benign prostatic hyperplasia (BPH) and median lobe obstruction

Global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Size, Forecast, and Trend Highlights Over 2023 - 2033

Base Year

2022

Forecast Year

2023-2033

CAGR

~6%

Base Year Market Size (2022)

~ USD 7.0 Billion

Forecast Year Market Size (2033)

~ USD 13.0 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of Middle East and Africa)

 

The global benign prostatic hyperplasia (BPH) prostate treatment market is estimated to garner robust revenue of ~USD 13.0 billion by the end of 2033 by growing at a CAGR of ~6% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of ~USD 7.0 billion in the year 2022. The growth of the market is attributed to the growing rate of BPH surgical treatment since it can cost one’s life. For instance, around 11,000 per 100,000 men received surgical treatment in 2018 which was an increase from approximately 9000 per 100,000 men in 2012.  

BPH  market overview imageGet more information on this report:Request Sample PDF

Benign prostatic hyperplasia (BPH), also known as prostate gland enlargement, is a medical condition that generally occurs in men above age of 60. Benign prostatic hyperplasia (BPH) is associated with any abnormalities in testicles. It is not a type of cancer but an overgrowth of prostate tissue resulting in the blockage of urine flow. Global benign prostatic hyperplasia (BPH) prostate treatment market trends such as, the higher prevalence of benign prostatic hyperplasia (BPH) and rising awareness of the disease is estimated to hike the growth of the market over the forecast period. For instance, benign prostatic hyperplasia becomes more prevalent in men after the age of 40 with a prevalence rate of approximately 10% to 65%.

Global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market: Growth Drivers and Challenges

Growth Drivers

  • Rising Geriatric Population- Figures demonstrated by the World Bank, it is estimated that the geriatric population reached 747,238,580 in 2021.Benign prostatic hyperplasia (BPH) prostate is a disease that occurs in the elder man. Since the number of geriatrics is high, the prevalence of benign prostatic hyperplasia (BPH) rises. It can be a severe health condition that requires immediate medical care.

  • Higher Prevalence of Benign Prostatic Hyperplasia (BPH)-Based on the report published by the National Institute of Diabetes and Digestive and Kidney Diseases, it is demonstrated that around 50% of men aged between 51 to 60 live with benign prostatic hyperplasia.

  • Developing Medical Technology Across the Globe - As of 2022, The growth of global medical technology was estimated to increase by approximately 4% per year.

  • Spiking Cases of Urinary Tract Infection - For instance, in the United States, approximately 0.9 million cases of UTIs are diagnosed every year.

  • Increasing Healthcare Expenditure per Capita- In 2019, the healthcare expenditure across the globe was estimated to be around 1000 U.S. dollars per capita.

Challenges

  • Possibility of Side-Effect of BPH Drugs

There can be significant side-effects of BPS drugs that can play as significant restraints factors. The side effects of benign prostatic hyperplasia (BPH) prostate treatment are dizziness, dry mouth, nasopharyngitis, pruritus, micturition difficulties, constipation, and others.

  • Government Initiatives Regarding the Sales and Consumption of Medicines

  • Lack of Awareness of the Disease in Developing Countries

The global benign prostatic hyperplasia (BPH) prostate treatment market is segmented and analyzed for demand and supply by treatment type into drug treatment and surgical treatment. Out of these, the drug treatment segment holds the highest market revenue in 2022 with a market share of approximately 58%. While on the other hand, the surgical treatment segment is expected to hold only 42% of the market share. The growth of the drug treatment segment is attributed to the rising consumption of drugs across the world. There are more than 20,000 prescription drugs approved in the United States for marketing. Also, about 70% of U.S. adults take prescription drugs. Also, the increment in sales of medicines from pharmacies is considered to be another growth factor of the segment. For instance, the sales of pharmacies and drug stores were projected to be around USD 300 billion in the USA in 2020.

Global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Regional Synopsis

The North America benign prostatic hyperplasia (BPH) prostate treatment market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033. The growth of market can be ascribed to the rising geriatric population and higher prevalence of benign prostatic hyperplasia. As per the data released by the World Bank, it was represented that in 2021, the geriatric population in the USA reached 56,545,938. Furthermore, the presence of major key players and the growing healthcare infrastructure of the region is further projected to influence the growth of the market positively over the forecast period.

Market Segmentation

Our in-depth analysis of the global benign prostatic hyperplasia (BPH) prostate treatment market includes the following segments:

     Treatment Type

  • Drug Treatment – 58%
  • Surgical Treatment – 42%

     By Therapeutic Class

  • BPH Devices
  • Transurethral RF Thermal Therapy
  • Suture Base Implant
  • Others
  • BPH Drugs
  • Alpha Blocker
  • Muscarinic Receptor Antagonist
  • 5-Alpha Reductase Inhibitors

 

     By Distribution Channels

  • Online Pharmacies
  • Retail
  • Institutional Sales

Top Featured Companies Dominating the Global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market

  • Pfizer Inc.

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis
  • Cardinal Health Inc.
  • NxThera, Inc.
  • NeoTract, Inc.
  • Teleflex Incorporated
  • Eli Lily & Company
  • Sanofi S.A.
  • GSK plc
  • Mylan N.V.
  • AbbVie Inc.

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions | LOB

Copyright © 2022 Research Nester. All Rights Reserved